QUOTE AND NEWS
Reuters  Aug 7  Comment 
The Bank of Portugal has received one improved bid for Novo Banco but will evaluate in coming weeks all three bids that have been made, the bank said on Friday.
FiercePharma  Aug 6  Comment 
Novo Nordisk keeps on putting up sales growth, with diabetes powerhouse Victoza leading the way. Its pipeline meds are moving along. But the question is whether that pipeline can start paying off soon enough to counteract increasing pricing...
Financial Times  Aug 6  Comment 
Danish drugmaker lifts full-year outlook but says Beijing’s anti-corruption drive has hit sales
FiercePharma  Aug 5  Comment 
Former NBA star Dominique Wilkins is not just a spokesman for Novo Nordisk's Victoza. He's also a prize in a Type 2 diabetes sweepstakes the drugmaker is rolling out.
Reuters  Jul 30  Comment 
The Bank of Portugal wants bidders for Novo Banco, the successor to Banco Espirito Santo (BES) following a state rescue last year, to come up with improved offers by Aug....
FierceBiotech  Jul 29  Comment 
Sanofi's combination of a Type 2 diabetes treatment and a long-acting insulin met its main goal in a Phase III trial, the company said, setting up an FDA application later this year.
GenEng News  Jul 27  Comment 
The shift from fully integrated pharmaceutical companies (FIPCOs) to virtually integrated pharma companies (VIPCOs) has made biopharmas more reliant on external R&D. Often, that external R&D comes from startups nurtured through the venture funds...
FierceBiotech  Jul 23  Comment 
KalVista Pharmaceuticals has persuaded Novo A/S, SV Life Sciences and some other notable VCs to part with $33 million (€29 million). The cash will go toward advancing KalVista's pipeline of plasma kallikrein inhibitors, the most advanced of...





You may also be interested in articles related to Novo Nordisk A/S (NVO):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki